Bovie Medical Corporation Announces Appointment of Scott R. Sanders as Director of Clinical Education and Market Development
March 27 2018 - 8:30AM
Business Wire
Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"),
a maker of medical devices and supplies and the developer of
J-Plasma®, a patented surgical product, today announced the
appointment of Scott R. Sanders as Director of Clinical Education
and Market Development.
“I am pleased to announce the addition of Scott Sanders to our
team, and look forward to leveraging his 37 years of clinical and
sales and marketing experience in the healthcare industry,
including over 29 years spent working with energy-based surgical
devices.” said Charlie Goodwin, Chief Executive Officer. “Mr.
Sanders will be instrumental in both establishing and implementing
our strategic plans to develop Bovie Medical’s clinical expertise
in the cosmetic surgery market and to enhance our physician and
practice support and training.”
Prior to joining Bovie Medical, Mr. Sanders was employed for
more than 16 years at Olympus Corporation and Gyrus ACMI. He joined
Gyrus (later Gyrus ACMI) in 2001 as a Business Unit Director, where
he was responsible for directing all activities in the company’s
laparoscopic business, including the introduction of new
electrosurgical products. He was promoted to Director and then Vice
President of Procedure and Product Development, where he directed
and managed the Company’s product marketing efforts and conducted
salesforce and surgeon clinical training across multiple surgical
disciplines and procedure categories.
In 2007, Mr. Sanders became Group Vice President of Procedure
and Product Development for Gyrus ACMI and continued to serve in
this role following the company’s acquisition by Olympus in 2008.
In this role, he assisted in the creation and implementation of
Olympus’s product development, clinical and reimbursement
strategies, overseeing departments including R&D, Clinical,
Reimbursement, Program Management and Product and Procedure
Development. Beginning in 2011, he served as Executive Director of
Clinical Marketing of Olympus’s global surgical energy group,
coordinating the company’s product development plans and providing
clinical training and support for its global salesforce and
physician customer base.
Before joining Olympus / Gyrus ACMI, Mr. Sanders worked for 13
years at Pfizer Valleylab in a variety of sales and marketing
positions of increasing responsibility, culminating in his
promotion to Director of Corporate Sales. Mr. Sanders holds a
Bachelor’s degree in Biology with minors in Chemistry, Physics and
Math from the University of Denver.
About Bovie Medical
Corporation:
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma®, a patented
plasma-based surgical product for cutting, coagulation and ablation
of soft tissue. J-Plasma® utilizes a helium ionization process to
produce a stable, focused beam of plasma that provides surgeons
with greater precision, minimal invasiveness and an absence of
conductive currents through the patient during surgery. The
new J-Plasma® handpieces with Cool-Coag™ technology deliver the
precision of helium plasma energy, the power of traditional
monopolar coagulation and the efficiency of plasma beam coagulation
- enabling thin-layer ablation and dissection and fast coagulation
with a single instrument, minimizing instrument exchange and
allowing a surgeon to focus on their patient and their
procedures. With Cool-Coag technology, the new J-Plasma
handpieces can deliver three distinctly different energy
modalities - further increasing the utility and versatility of the
J-Plasma system. Bovie Medical Corporation is also a leader in the
manufacture of a range of electrosurgical products and
technologies, marketed through both private labels and the
Company’s own well-respected brands (Bovie®, IDS™ and DERM™) to
distributors worldwide. The Company also leverages its expertise
through original equipment manufacturing (OEM) agreements with
other medical device manufacturers. For further information about
the Company’s current and new products, please refer to the
Investor Relations section of Bovie Medical Corporation
at www.boviemed.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
Forward-looking information is subject to certain risks, trends
and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the Company's ability to control or predict. Important factors that
may cause actual results to differ materially and that could impact
the Company and the statements contained in this release can be
found in the Company's filings with the Securities and Exchange
Commission including the Company's Report on Form 10-K for the year
ended December 31, 2017 and subsequent Form 10-Q filings. For
forward-looking statements in this release, the Company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of
1995.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180327005357/en/
Investor Relations
Contact:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino,
CFA443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bovie (AMEX:BVX)
Historical Stock Chart
From Sep 2023 to Sep 2024